Psomagen Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
88
- Stock Symbol
-
950200
- Investments
-
6
- Share Price
-
$1.93
- (As of Friday Closing)
Psomagen General Information
Description
Psomagen Inc provides total genomic solutions for both clinical and research purposes. It is mainly focused on end-to-end sequencing services. The company also offers services such as personal DNA tests, clinical sequencing, research sequencing, and others.
Contact Information
Website
www.psomagen.comCorporate Office
- 1330 Piccard Drive
- Suite 103
- Rockville, MD 20850
- United States
Corporate Office
- 1330 Piccard Drive
- Suite 103
- Rockville, MD 20850
- United States
Psomagen Stock Performance
As of 20-Nov-2026, Psomagen’s stock price is $1.93. Its current market cap is $37.2M with 19.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.93 | $1.95 | $1.54 - $3.37 | $37.2M | 19.2M | 376K | -$0.06 |
Psomagen Financials Summary
As of 31-Mar-2026, Psomagen has a trailing 12-month revenue of $42.8M.
|
In Thousands, USD |
TTM 31-Mar-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 44,676 | 52,819 | 49,150 | 69,265 |
| Revenue | 42,774 | 41,593 | 32,001 | 24,685 |
| EBITDA | 1,547 | 1,210 | (720) | (442) |
| Net Income | (1,134) | (2,096) | (4,117) | (3,280) |
| Total Assets | 35,292 | 34,571 | 37,636 | 34,607 |
| Total Debt | 9,915 | 9,164 | 7,679 | 3,872 |
Psomagen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Psomagen Comparisons
Industry
Financing
Details
Psomagen Competitors (5)
One of Psomagen’s 5 competitors is Novogene, a Formerly PE-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novogene | Formerly PE-Backed | Beijing, China | ||||
| Viome Life Sciences | Venture Capital-Backed | Bellevue, WA | ||||
| Agendia | Venture Capital-Backed | Irvine, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Hummingbird Bioscience | Venture Capital-Backed | Singapore, Singapore |
Psomagen Patents
Psomagen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021206480-A1 | Composition and method for an antibiotic-inducing imbalance in microbiota | Inactive | 08-Apr-2020 | ||
| US-11781132-B2 | Dna extraction method using microwave for next generation sequencing and use thereof | Active | 05-Nov-2019 | ||
| US-20210130812-A1 | Dna extraction method using microwave for next generation sequencing and use thereof | Active | 05-Nov-2019 | ||
| JP-2022527802-A | By-products of the microbial flora and their use | Pending | 29-Mar-2019 | ||
| AU-2020256101-A1 | Microbiome byproducts and uses thereof | Inactive | 29-Mar-2019 | G16B40/20 |
Psomagen Signals
Psomagen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Psomagen Investments (6)
Psomagen’s most recent deal was a Later Stage VC with ImmuneMed. The deal was made on 02-Nov-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ImmuneMed | 02-Nov-2021 | Later Stage VC | Diagnostic Equipment | ||
| Ubiome (patents and data in San Francisco, California) | 02-Jan-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Seonglim (Daebong Building in Seoul, South Korea) | 28-Jun-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Microba | 01-Jun-2019 | Early Stage VC | Laboratory Services (Healthcare) | ||
| 3billion | 01-Jan-2018 | Early Stage VC | Diagnostic Equipment |
Psomagen Exits (3)
Psomagen’s most recent exit was on 01-Jun-2019 from Microba. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Microba | 01-Jun-2019 | Completed |
|
||
| 3billion | 01-Jan-2018 | Completed |
|
||
| BioMicro Systems | 17-Jan-2001 | Early Stage VC | Completed |
|
Psomagen FAQs
-
When was Psomagen founded?
Psomagen was founded in 1997.
-
Where is Psomagen headquartered?
Psomagen is headquartered in Rockville, MD.
-
What is the size of Psomagen?
Psomagen has 88 total employees.
-
What industry is Psomagen in?
Psomagen’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Psomagen a private or public company?
Psomagen is a Public company.
-
What is Psomagen’s stock symbol?
The ticker symbol for Psomagen is 950200.
-
What is the current stock price of Psomagen?
As of 20-Nov-2026 the stock price of Psomagen is $1.93.
-
What is the current market cap of Psomagen?
The current market capitalization of Psomagen is $37.2M.
-
What is Psomagen’s current revenue?
The trailing twelve month revenue for Psomagen is $42.8M.
-
Who are Psomagen’s competitors?
Novogene, Viome Life Sciences, Agendia, Genetix Biotherapeutics, and Hummingbird Bioscience are competitors of Psomagen.
-
What is Psomagen’s annual earnings per share (EPS)?
Psomagen’s EPS for 12 months was -$0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process